

CLARITY
PHARMACEUTICALS

Managing Director's presentation

Annual General Meeting
20 November 2024

Michelle Parker

Disclaimer

Introduction
This presentation has been prepared by Clarity Pharmaceuticals Ltd (ACN 143 005 341) (**Clarity** or the **Company**) and contains summary information about Clarity and the business conducted by it as at 20 November 2024. The information in this presentation is for general informational purposes only, does not purport to be complete or comprise all information which a shareholder or potential investor may require in order to determine whether to deal in Clarity shares. It should be read in conjunction with the Company's IPO prospectus and other periodic and continuous disclosure announcements lodged with the ASX.

This presentation is not a prospectus, product disclosure statement or other disclosure document for the purposes of Chapter 6D or Part 7.9 of the Corporations Act 2001 (Cth) (**Act**) or other offer document under Australian law or the law of any other jurisdiction, including the United States.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and the opinions expressed are fair and reasonable, none of Clarity, nor its advisers (**Advisers**) nor their respective affiliates, related bodies corporate (as defined in the Act) or securityholders and their respective directors, officers, employees, partners, representatives, consultants, agents or advisers (each a **Limited Party** and together, the **Limited Parties**) make any representation or warranty to, or takes responsibility for, the content of this presentation, and nothing contained in this document is, or may be relied upon as, a promise or representation, whether as to the past or future. To the maximum extent permitted by law, the Limited Parties disclaim all liability and responsibility (including without limitation any liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use or reliance on anything contained in, or omitted from, this presentation.

Forward looking statements
The information contained in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of Clarity's views on future performance or condition. Past performance cannot be relied upon as an indicator of future performance. This presentation contains certain forward-looking statements. The words "forecast", "estimate", "like", "anticipate", "opinion", "believe", "expect", "project", "predict", "intend", "propose", "should", "could", "may" and other similar expressions are intended to identify future earnings, financial position and performance of Clarity. You are cautioned not to place undue reliance on these statements. These forward-looking statements are based on estimates, projections and assumptions made by Clarity about circumstances and events that have not yet taken place. Although due care and attention has been used in the preparation of these statements, such forward-looking statements are based on numerous assumptions regarding Clarity's present and future business strategies and the political, regulatory and economic environment in which Clarity will operate in the future, and are subject to change without notice. Statements about market and industry trends, which are based on interpretations of current market conditions, may not be reasonable, and are not guarantees or predictions of future performance. Actual results from any clinical trial may vary from any result that is anticipated. Under no circumstances will anything in this presentation create an implication that there has been no change in the affairs of the Company since the date of this presentation.

The actual results or performance of Clarity may be materially different from the results or performance expressed or implied by such forward-looking statements.

No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including any of the Limited Parties). In particular, no representation, warranty or assurance (express or implied) is given that the occurrence of the events expressed or implied in any forward-looking statement in this presentation will actually occur. Subject to any continuing obligations under applicable law, the Company expressly disclaims any obligation or undertaking to provide any updates or revisions to any forward-looking statements in this presentation to reflect any change in expectations in relation to any forward-looking statement or any change in events, conditions or circumstances on which any statement is based.

Not an offer or financial product advice
The information contained in this presentation is for informational purposes only and should not be considered, and does not contain or purport to contain, an offer, invitation, solicitation or recommendation with respect the purchase or sale of any securities in Clarity (**Securities**) nor does it constitute legal, taxation, financial product or investment advice. The general information in this presentation has been prepared without taking into account the investment objectives, financial situation or particular needs of any particular person. This presentation does not constitute an advertisement for an offer or proposed offer of Securities. Investors must undertake their own independent investigations, consideration and evaluation. Neither this presentation nor any of its contents will form the basis of any contract or commitment and it is not intended to induce or solicit any person to engage in any transaction nor is it intended to be used as the basis for making an investment decision. This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of, any "US person" as defined in Regulation S under the US Securities Act of 1993 (**Securities Act**).

Clarity recommends that potential investors consult their professional advisors as an investment in Clarity is subject to investment and other known and unknown risks, some of which are beyond the control of Clarity or its directors and therefore any investment is considered to be speculative in nature.

Market and industry data and other information
Certain market and industry data and other information used in this presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither the Company nor its representatives or its advisers have independently verified, or can assure investors as to the accuracy of, any market or industry data or other information provided by third parties or industry or general publications. Photographs and diagrams used in this presentation that do not have descriptions are for illustration only and should not be interpreted to mean that any person shown in them endorses this presentation or its contents or that the assets shown in them are owned by the Company. Diagrams used in this presentation are illustrative only and may not be drawn to scale.

General
Statements made in this presentation are made only as at the date of this presentation. The information in this presentation remains subject to change without notice. The Company may in its absolute discretion, but without being under any obligation to do so, update or supplement this presentation. Any further information will be provided subject to the terms and conditions contained in this Disclaimer.

Key FY24 highlights

CLINICAL & REGULATORY

- Actively progressing 7 clinical trials + 1 IIT of Clarity's three key product areas
- ^{64}Cu-SAR-bisPSMA Phase III diagnostic trial ongoing with another Phase III trial commencing shortly
- Fast-Track Designation for ^{64}Cu-SAR-bisPSMA pre-prostatectomy
- Initial therapy data with ^{67}Cu-SAR-bisPSMA is very encouraging

OPERATIONS

- NorthStar manufacturing commercial scale Cu-67 and ^{67}Cu-SAR-bisPSMA final drug product under one roof for Phase I/II and Phase III trials
- Nucleus RadioPharma manufacturing ^{67}Cu-SAR-bisPSMA drug product for Phase I/II and Phase III trials
- SpectronRx manufacturing Cu-64 and ^{64}Cu-SAR-bisPSMA diagnostic product
- Supply agreement for Ac-225 with TerraPower

PEOPLE & CULTURE

- Grown the team to 62 employees in the U.S. and Australia
- Approx. 15 promotions in the last year
- Growing senior executive team & aligning roles of existing team members

FINANCIAL

- Strong cash balance of $123.7 million as at 30 September 2024
- Anticipated R&D tax incentive for FY24: ~$11 million
- Cash runway to fund existing trial pipeline and provide cash runway to 2026
- Continued strong capital markets for radiopharm

Three core product areas in clinical trials

Clarity has potential to address multiple oncology indications with unmet needs through a range of products and their applications. These include large indications, such as prostate and breast cancers, as well as small and orphan indications, such as neuroendocrine tumours (NETs) and neuroblastoma, an aggressive childhood cancer.



Each product class can be used as:

- A stand-alone ^{64}Cu-based diagnostic
- Combined as a theranostic using ^{64}Cu-labelled products to select patients for therapy with ^{67}Cu-labelled products

Clinical stage assets in multiple cancers

Clarity's products are progressing through sponsored clinical trials in the U.S. and Australia

Clinical development pipeline as of 20 November 2024

Indication	Product	Application	Current Trial
Prostate Cancer	SAR-bisPSMA	Theranostic mCRPC	SECURE
	SAR-bisPSMA	Diagnostic in pre-radical prostatectomy	CLARIFY
	SAR-bisPSMA	Diagnostic in BCR PCa	AMPLIFY
	SAR-BBN	Diagnostic in BCR PCa	SABRE
	SAR-BBN	Theranostic mCRPC	COMBAT
Neuroblastoma	SARTATE	Theranostic	CL04
NETs	SARTATE	Diagnostic	DISCO
SAR Discovery Platform	Ac-225 bisPSMA	Theranostic	
	TCT and I/O combination	Theranostic	
	Pan-cancer TCT	Theranostic	
	Multiple novel TCTs	Theranostic	



Current progress

12 month progress

Note clinical development pipeline is indicative only, subject to review.

All U.S. studies are conducted under Investigational New Drug Applications

SAR-bisPSMA

Targets the Prostate Specific Membrane Antigen (PSMA), present in the majority of prostate cancers



Co-PSMA - Phase II Investigator-Initiated Trial (IIT)

- Led by Prof Louise Emmett at St Vincent's Hospital Sydney
- Evaluates the performance of ^{64}Cu-SAR-bisPSMA in comparison to standard-of-care ^{68}Ga-PSMA-11 product for the detection of prostate cancer recurrence
- First patient first visit expected soon

SECuRE - Phase I/IIa

- Cohort 4 ongoing - 2 therapy cycles (12GBq)
- No DLTs observed to date
- First 3 participants in Cohort 4 had reductions in prostate-specific antigen (PSA) levels following 2 doses of 12GBq of ^{67}Cu-SAR-bisPSMA, with the largest drop being 98% to date

CLARIFY - Phase III

- Registrational Phase III imaging trial of participants with high-risk prostate cancer prior to radical prostatectomy using ^{64}Cu-SAR-bisPSMA
- Fast-Track Designation granted by the U.S. FDA
- Recruitment ongoing

COBRA - Phase I/II

- Positive results released with data used to support the End of Phase meeting with the U.S. FDA
- COBRA abstract selected as a Top-Rated Oral Presentation at EANM 2024 Congress

AMPLIFY – Phase III

- Registrational Phase III imaging trial with ^{64}Cu-SAR-bisPSMA in prostate cancer patients with biochemical recurrence (BCR)
- Recruitment will commence early 2025

SAR-bisPSMA market opportunity

PSMA based diagnostics

- Current U.S. patient pool for PSMA-PET imaging is **~400k** scans per year between initial staging, suspected recurrence and patient selection for targeted therapy
- At US$5,000 per patient dose this represents a U.S. market potential of **~US$2Bn/**year
- By 2030 this is expected to grow to **>700k** scans per year, representing a U.S. market potential of **>US$3Bn/year**
- 2025 CMS reimbursement changes favour the long-term potential of the best-in-class PSMA PET agent

Quarterly US Sales ($M USD) - PSMA PET Diagnostics



*Locametz & Posluma sales are estimations

SAR-bisPSMA aims to disrupt current diagnostic and therapeutic utilisation as a best-in-class agent for imaging and treating prostate cancer

PSMA based therapy (mCRPC)

- Current U.S. market opportunity (post chemo): **>US$5Bn**
- Future U.S. market opportunity (including pre-chemo): **>US$10Bn**
- Pluvicto reached blockbuster status in Q3 2024 with sales exceeding **US$1Bn**

Therapy program with ^{67}Cu-SAR-bisPSMA

Trial overview

- Phase I/II study in mCRPC
- Participants do not need to have received chemotherapy
- Dose escalation followed by cohort expansion with up to 4 cycles of therapy



SECuRE

Trial highlights to date

- Cohort 3 completed, now progressing the final 3 patients in cohort 4 at 12GBq (Pluvicto dose capped at 7.4GBq)
- First 3 participants in Cohort 4 had reductions in prostate-specific antigen (PSA) levels following 2 doses of 12GBq of ^{67}Cu-SAR-bisPSMA, with the largest drop being 98% to date
- No DLTs have been observed to date
- Cohort 4 will be followed by a cohort expansion phase of the trial, pending safety evaluation

Before single cycle (8GBq) 24 May 2023

After treatment 10 Aug 2023



CLARITY PHARMACEUTICALS

^{67}Cu-SAR-bisPSMA single dose leads to PSA reductions in heavily pre-treated mCRPC patients



78%

of patients showed reductions in PSA levels >35% (cohorts 2 and 3)

44%

of patients showed reductions in PSA levels >80% (cohorts 2 and 3)

PSA reductions shown as the response observed post-single dose of ^{67}Cu-SAR-bisPSMA. PSA pre-dose value represents the most recent test result prior to the administration of ^{67}Cu-SAR-bisPSMA. At study entry, patients had median PSA of 117.1 ng/ml.

Data on file. Data cut-off: 6 March 2024 for PSA levels; 3 April 2024 for demographics. NCT04868604.

Radiographic partial response and PSA80 following 2 cycles of ^{67}Cu-SAR-bisPSMA (12GBq)

Pre-^{67}Cu-SAR-bisPSMA	Post-cycle 2 of ^{67}Cu-SAR-bisPSMA



PSA reduction following 3 cycles of ^{67}Cu-SAR-bisPSMA



rPR

61% tumour volume reduction following **2 cycles**

↓98%

PSA reduction following **3 cycles**

mCRPC patient from cohort 4 showing extensive metastasis to the lymph nodes (regions highlighted by the red lines, images on the left). ^{64}Cu-SAR-bisPSMA images show reduction in tumour volume from pre- to post-treatment with ^{67}Cu-SAR-bisPSMA (2 cycles, 12GBq). rPR: radiographic partial response by RECIST v1.1 assessment. PSA reduction: nadir not reached (from 157.4 to 3.2 ng/mL). Images shown as maximum intensity projections. Data cut-off 15 Nov 2024.

CLARITY PHARMACEUTICALS

^{67}Cu-SAR-bisPSMA has a favourable safety profile

Cohorts 1-3 Adverse event (AE)	Grade 3 N = 15 (100%)
Any drug-related AEs	3 (20)
Occurring in at least 1 participant	
Anaemia	2 (13)
Thrombocytopenia	1 (7)
Leukopenia	1 (7)
Lymphopenia	1 (7)

Demographics summary: all participants had mCRPC at study entry. Median number of lines of therapy prior to receiving ^{67}Cu-SAR-bisPSMA: 4 (range 2-6). Previous treatments included ADT, ARPI, investigational agents, chemotherapy (67%, 10/15) and other radioligand therapies. Median PSA at study entry: 117.1 ng/ml (range 0.11-1,494.2).

SECURE

Cohorts 1-3 (single dose): most adverse events (AEs) were lower Grade, with only 3/15 patients developing Grade 3 AEs (no Grade 4/5)

- No AEs were related to ^{64}Cu-SAR-bisPSMA
- AEs were reported as related to ^{67}Cu-SAR-bisPSMA in 8 out of the 15 trial participants (all Grades)
- Most AEs related to ^{67}Cu-SAR-bisPSMA were Grade 1 or 2
- No Grade 4 or 5 AEs were reported in the study

Cohort 4 (multi-dose): almost all AEs were mild or moderate (majority either resolved or improved at the last assessment). No DLTs observed.

Data on file. Data cut of: 6 March 2024. NCT04868604.

^{67}Cu-SAR-bisPSMA adaptive dosing leads to durable PSA response and disease control: EAP case report 1

Pre-^{67}Cu-SAR-bisPSMA

Post-^{67}Cu-SAR-bisPSMA (4 cycles x 4GBq)



05 Oct 2022 *(baseline)*

24 Jul 2024 *(14 months after the 4th dose of ^{67}Cu-SAR-bisPSMA)*

PSA reduction following multi-doses of ^{67}Cu-SAR-bisPSMA



mCRPC patient with metastasis to the bones (blue arrows, images). Definitive radiation therapy in 2013. Previous systemic therapies: ADT, 2 ARPIs. Images show reduction in lesion uptake (^{64}Cu-SAR-bisPSMA PET) following 4 doses of ^{67}Cu-SAR-bisPSMA (4GBq each), with reduction in PSA of 94.4%. Reduction in SUVmax and tumour volume: 72.5% and 41.6%, respectively. New bone lesions detected in latest PET (red circles, approximately 14 months post-4th dose of ^{67}Cu-SAR-bisPSMA). Recent rising in PSA led to the administration of a 5th cycle of ^{67}Cu-SAR-bisPSMA (8GBq). PSA reduction of 47.52% vs latest PSA peak (10.1 ng/mL; PSA continues to decline). AE related to ^{67}Cu-SAR-bisPSMA: mild (Grade 1) thrombocytopenia (improving). Images: maximum intensity projection. Graph dash lines: administration of ^{67}Cu-SAR-bisPSMA. EAP: Expanded Access Program. Data cut-off 28 Sep 2024.

^{67}Cu-SAR-bisPSMA adaptive dosing leads to durable **complete response**: EAP case report 2

- Complete **anatomical** response (CT; RECIST v1.1)
- Complete **molecular** response (PET)
- Complete **biochemical** response (undetectable PSA)

Pre-^{67}Cu-SAR-bisPSMA	Post-^{67}Cu-SAR-bisPSMA (Two cycles, 8GBq each)



24 May 2023 *(baseline)*



22 Nov 2023 *(5.7 months after the 1st dose of ^{67}Cu-SAR-bisPSMA)*

PSA reduction following 2 cycles of ^{67}Cu-SAR-bisPSMA



Images: PET scan showed no uptake of ^{64}Cu-SAR-bisPSMA above the background level following 2 doses of ^{67}Cu-SAR-bisPSMA, demonstrating a complete molecular response. Dash lines in graph: administration of ^{67}Cu-SAR-bisPSMA. Safety: xerostomia (Grade 1), fatigue (Grade 2), both resolved; dysgeusia (Grade 1), improved; thrombocytopenia (Grade 1); anaemia (Grade 3, improved to Grade 2). EAP: Expanded Access Program. PSA limit of detection 0.05 ng/mL. PSA limit of detection: 0.05 ng/ml. Images: maximum intensity projection. Data cut-off 14 Oct 2024.

Diagnostic program with ^{64}Cu-SAR-bisPSMA

Trial overview

- Phase III registrational trial in high-risk prostate cancer patients prior to undergoing radical prostatectomy and pelvic lymph node dissection
- Assessing same-day and next-day imaging of ^{64}Cu-SAR-bisPSMA in this patient population
- Recruitment is ongoing



1. Screening
2. ^{64}Cu-SAR-bisPSMA administration followed by PET/CT scan
3. "Same day" and "next day" imaging
4. Surgical removal of the prostate and pelvic lymph nodes
5. Laboratory assessments (histopathology) to confirm the results of the PET scan

CLARITY PHARMACEUTICALS

CLARIFY

U.S. FDA Fast Track Designation (FTD)

- U.S. FDA granted FTD for ^{64}Cu-SAR-bisPSMA for PET imaging of PSMA positive prostate cancer lesions with suspected metastasis who are candidates for initial definitive therapy
- FTD is designed to expedite the development and regulatory review of novel drugs addressing serious conditions with significant unmet medical need
- Fast track products must show advantage over available therapy

Key benefits

- Potentially faster product approval review process
- More frequent communication with the FDA
- Rapid query resolution
- Clarity can submit sections as they are completed rather than waiting for complete application package

SAR-bisPSMA is safe and effective in detecting tumours in prostate cancer patients

COBRA

Clinicians reported they would change their treatment plan in approximately 50% of patients due to ^{64}Cu-SAR-bisPSMA scans, signalling a potential material improvement in patient care

Patients with negative/equivocal SOC scans - COBRA study (biochemical recurrence)

82% more lesions detected on next-day imaging (2 mm-range)



34% more patients with a positive scan on next-day imaging



CLARITY PHARMACEUTICALS

Left images. Up to 80 lesions detected on same-day imaging vs. up to 153 lesions on next-day imaging across all participants. Right images: pelvic lymph node detected by ^{64}Cu-SAR-bisPSMA on next-day imaging, but not with Pylarify® at screening. Patients with a positive ^{64}Cu-SAR-bisPSMA scan: from up to 58% to up to 80%, same and next-day imaging respectively). Nordquist et al., SNMMI 2024.

Higher uptake and contrast in lesions on next-day imaging and detection of lesions in the 2mm range

COBRA



Figure 1. Pelvic lymph nodes showing uptake of ^{64}Cu-SAR-bisPSMA on next-day imaging (arrows, B and D). Blue arrow: lesion size 3.8 mm x 4.4 mm, SUVmean 20.6, SUVmax 22.1 and TBR 130.1. Green arrow: lesion size also 3.8 mm x 4.4 mm, SUVmean 11.9, SUVmax 12.8 and TBR 75.3. Red arrow: size >5 mm. Inset in top images (A, B) displays pelvic region (bottom images, C and D).



>80% increase in mean SUVmean and SUVmax
(same-day vs. next-day imaging)



>5x higher mean TBR
(same-day vs. next-day imaging)

Figure 2. SUVmean/max and TBR comparing same-day (Day 0) and next-day (Day 1) imaging. Average increase across 3 readers. SUVmean: mean standardised uptake value. SUVmax: maximum standardised uptake value. TBR: tumour-to-background ratio. The SUVmax, SUVmean and TBR were assessed in up to 25 lesions per patient on each ^{64}Cu-SAR-bisPSMA scan. Ranges across the readers for same-day and next-day imaging, respectively: SUVmean 6.6-9.9 and 14.7-15.8; SUVmax 13.9-14.0 and 22.2-33.4; TBR 23.2-25.4 and 118.1-181.7. TBR = SUVmax of the lesions / SUVmean of the gluteus region.

Nordquist et al. COBRA study. SNMMI, 2024.

SAR-Bombesin

Targets the Gastrin Releasing Peptide receptor (GRPr), which is present in a number of cancers, including breast and prostate cancers





Single pelvic lymph node uptake seen on ^{64}Cu-SAR-Bombesin on both Day 1 and Day 2. A subsequent biopsy has confirmed prostate cancer.

COMBAT – Phase I/IIa therapy

- ^{64}Cu-SAR-BBN and ^{67}Cu-SAR-BBN for identification and treatment of GRPr-expressing mCRPC in patients who are ineligible for therapy with ^{177}Lu-PSMA-617
- Progressing through dose escalation across 5 sites in the U.S.
- Presented at ASCO GU (Jan 24) and SNMMI (Jun 24)

SABRE – Phase II

- Phase II PET imaging trial of participants with PSMA-negative BCR of prostate cancer using ^{64}Cu-SAR-BBN
- Follow up period completed with data review and analysis ongoing
- Initial data readout anticipated Q1 2025
- Presented at ASCO GU (Jan 24) and SNMMI (Jun 24)

BOP – Phase II

- Investigator Initiated PET imaging trial of participants with negative PSMA PET or low PSMA expression disease in patients with suspected BCR of prostate cancer and patients with mCRPC using ^{64}Cu-SAR-BBN led by Prof Louise Emmett at St Vincent's Hospital Sydney
- Manuscript published in the Journal of Nuclear Medicine (Aug 2024)

SABRE ClinicalTrials.gov identifier: NCT05407311

SARTATE

Targets the Somatostatin Receptor 2 (SSTR2), which is present in an aggressive childhood cancer, neuroblastoma, as well as neuroendocrine tumours (NETs), among other cancers

High Accuracy

High Precision



^{123}I MIBG
Current Standard of Care

^{64}Cu SARTATE™
PET screening
4 hours

^{67}Cu SARTATE™
SPECT scan
24 hours

(in the same patient)



CL04 – Phase I/IIa

- **^{64}Cu/^{67}Cu-SARTATE** theranostic clinical trial in high-risk neuroblastoma
- Cohort 4 recently completed. Update provided shortly.

DISCO – Phase II

- A diagnostic imaging study of ^{64}Cu-SARTATE using PET on patients with known or suspected NETs
- Recruitment closed with final patients soon to complete the follow-up period
- Initial data readout anticipated mid 2025

CL04 ClinicalTrials.gov identifier: NCT04023331

Scaling manufacturing for commercial launch

Clarity continues to strengthen and expand its manufacturing and supply chain footprint, creating additional capacity and flexibility to supply products to any state in the U.S. for upcoming and ongoing late-stage clinical trials

NorthStar MEDICAL RADIOISOTOPES, LLC

Clinical Supply Agreement for ^{67}Cu-SAR-bisPSMA

Large-scale manufacturing of copper-67 isotope and cGMP ^{67}Cu-SAR-bisPSMA drug product in the U.S. under one roof

Nucleus RadioPharma

Drug manufacturing of ^{67}Cu-SAR-bisPSMA

Manufacturing the ^{67}Cu-SAR-bisPSMA drug product at Nucelus RadioPharma's state-of-the-art facility in Rochester, MN

SpectronRx

Supply Agreement for the production of Cu-64

The first private supplier of Cu-64 to join Clarity's network in the U.S., which will support the Company as it progresses towards commercial launch

TerraPower

Actinium-225 program

Supply of therapeutic alpha-emitting actinium-225 for Clarity's Targeted Alpha-particle Therapy (TAT) program with bisPSMA

Highly experienced team

Dr Alan Taylor
Executive Chairman

Michelle Parker
CEO

Dr Colin Biggin
COO

Eva Lengyelova
EVP – Clinical Development

Shaemus Gleason
EVP - Operations

Dr Othon Gervasio
Chief Medical Officer

Dr Matt Harris
Chief Technology Officer

Mary Bennett
Head of People and Culture

Robert Vickery
Company Secretary

Kathryn Williams-Day
VP - Regulatory Affairs and Quality

David Green
Chief Financial Officer

ALGETA MERCK
CardinalHealth™ BAYER
Viralytics SANDOZ
NOVARTIS sanofi

Clarity's management team has a diverse and in-depth level of expertise spanning corporate finance, management, clinical, operations, commercialisation and industry

- Development, approval and launch of 1st approved radiopharmaceutical therapy product for prostate cancer (Xofigo)
- Decades of experience spanning across science, nuclear medicine/PET and pharmaceutical industries
- Investment banking experience focused on the life sciences sector

CLARITY PHARMACEUTICALS

Thank you

Contact details

Dr Alan Taylor
Executive Chairperson
E: alan.taylor@claritypharm.com

Michelle Parker
Managing Director
E: Michelle.Parker@claritypharmaceuticals.com